在患有勒维体痴呆症的患者中,多尼佩西尔与骨折风险之间的关系
Shoya Matsumoto1, Mitsutaka Yakabe1, Tatsuya Hosoi1
1Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Geriatrics & gerontology international
|June 26, 2024
概括
在老年痴呆症的勒维体 (DLB) 患者中,多尼佩西尔的使用显著降低了关节骨折的风险. 这项研究表明,多尼佩西尔除了对DLB的认知症状管理之外,还提供了额外的好处.
科学领域:
- 老年医学 老年医学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有勒维体痴呆症 (DLB) 患者面临高风险的跌倒和骨折.
- 胆酶抑制剂用于DLB的认知症状,但它们对骨折风险的影响尚不清楚.
研究的目的:
- 调查使用多尼佩西尔与老年DLB患者部骨折风险之间的关联.
- 评估多尼佩西尔在DLB中减少骨折的潜在益处.
主要方法:
- 对65岁以上DLB患者的日本保险索赔数据库 (2012年4月至2019年3月) 的分析.
- 倾向性得分匹配被用来比较多尼西尔和那些没有服用抗痴呆药物的DLB患者之间的3年关节骨折率.
主要成果:
- 分析了1182对DLB患者的倾向分数匹配对.
- 在接受多内西尔的DLB患者中,骨骨折发病率明显较低 (0.60/100人/年),与未接受抗痴呆药物 (1.44/100人/年) 患者相比.
- 两组之间没有观察到脊椎骨折率的显著差异.
结论:
- 在日本老年DLB患者中,多尼佩西尔的使用与部骨折的风险显著降低有关.
- 多尼可能为DLB患者提供额外的治疗益处,包括减少骨折风险.
相关概念视频
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Parkinson's Disease: Treatment
254
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
254
Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523
Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K


